| Selpercatinib | Eli Lilly | ||
| 40 mg and 80 mg ; Capsule |
Less Than $1000 mn
|
||
| None | None | ||
|
Less Than 5
|
None | ||
| None | None | ||
| RETEVMO ® is a kinase inhibitor indicated for the treatment of: • Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test • Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy • Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) • Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. | |||
|
Yes
| |||
| Retevmo | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 |
|---|---|---|---|---|---|
| ******* ******* | |||||
| *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ***** | ************ ** *-(*-*******-*-************)-*-(*-(*-((*-**************-*-**)******)-*,*-************[*.*.*]******-*-**)*******-*-**)********[*,*-*]********-*-************ |
| Selpercatinib | None | ||
| 40MG, 80MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| RETEVMO® is a kinase inhibitor indicated for the treatment of: • Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. • Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. • Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)1 • Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options . This indication is approved under accelerated approval based on overall respon | |||
|
Yes
| |||
| Retevmo | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ***** | ************ ** *-(*-*******-*-************)-*-(*-(*-((*-**************-*-**)******)-*,*-************[*.*.*]******-*-**)*******-*-**)********[*,*-*]********-*-************ | ************ ** *-(*-*******-*-*************)-*-(*-(*-((*-**************-*-**)******)-*,*-************[*.*.*]******-*-**)*******-*-**)********[*,*-*]********-*-************ | ************ ** *-(*-*******-*-*************)-*-(*-(*-((*-**************-*-**)******)-*,*-************[*.*.*]******-*-**)*******-*-**)********[*,*-*]********-*-************ |
| Selpercatinib | None | ||
| 120MG, 160MG, 40MG, 80MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| RETEVMO® is a kinase inhibitor indicated for the treatment of: • Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. • Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. • Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)1 • Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options . This indication is approved under accelerated approval based on overall respon | |||
|
Yes
| |||
| Retevmo | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ********[*,*-*]******** ********* ** *** ****** ********** | *********** ***** | ************ ** *-(*-*******-*-************)-*-(*-(*-((*-**************-*-**)******)-*,*-************[*.*.*]******-*-**)*******-*-**)********[*,*-*]********-*-************ | ************ ** *-(*-*******-*-*************)-*-(*-(*-((*-**************-*-**)******)-*,*-************[*.*.*]******-*-**)*******-*-**)********[*,*-*]********-*-************ | ************ ** *-(*-*******-*-*************)-*-(*-(*-((*-**************-*-**)******)-*,*-************[*.*.*]******-*-**)*******-*-**)********[*,*-*]********-*-************ |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|